Baxter International Inc. reported its first-quarter 2025 results, showing a 5% increase in sales from continuing operations, totaling $2.63 billion. This growth exceeded the company's previous guidance. The company's net income from continuing operations totaled $64 million, or $0.13 per diluted share on a U.S. GAAP basis. On an adjusted basis, earnings per share from continuing operations were $0.55, surpassing initial guidance of $0.47 to $0.50 per diluted share. International sales amounted to approximately $1.14 billion, showing a 1% decline on a reported basis but a 3% increase operationally. Baxter's segments all demonstrated growth on both reported and operational bases. The Medical Products & Therapies segment, for instance, recorded sales of approximately $1.26 billion, with a 3% increase on a reported basis and a 6% rise operationally, driven by strong demand in the U.S. for infusion therapies and technologies. Looking forward, Baxter now anticipates full-year 2025 sales growth from continuing operations of 7% to 8% on a reported basis and 4% to 5% operationally. The adjusted earnings from continuing operations are expected to range between $2.47 and $2.55 per diluted share. For the second quarter of 2025, Baxter forecasts sales growth from continuing operations of 4% to 5% on a reported basis and 1% to 2% operationally, with adjusted earnings per diluted share anticipated to be between $0.59 and $0.63.